Join
Live feed
·
PRReleasevia Quantisnow
NGM Biopharmaceuticals Inc. logo

NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

ByQuantisnow·Wall Street's wire, on your screen.
NGM· NGM Biopharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NGM (NGM Biopharmaceuticals Inc.) and more on Quantisnow.